Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23388730 | 0.86 | MAPT (0.59) | MAPTKMT2AALDH1A1MEN1GPR119 | |
| SCHEMBL8260715 | 0.86 | USP2 (0.75) | MAPTKMT2AALDH1A1MEN1GPR119 | |
| SCHEMBL15801114 | 0.85 | MAPT (0.71) | MAPTKMT2AALDH1A1MEN1NPC1 | |
| SCHEMBL17669252 | 0.85 | MAPT (0.71) | MAPTKMT2AALDH1A1MEN1NPC1 | |
| SCHEMBL3773829 | 0.84 | MAPT (0.57) | MAPTKMT2AALDH1A1MEN1GPR119 | |
| SCHEMBL1662934 | 0.84 | USP2 (0.72) | MAPTKMT2AALDH1A1MEN1USP2 | |
| SCHEMBL1438476 | 0.83 | KMT2A (0.60) | MAPTKMT2AALDH1A1MEN1GPR119 | |
| SCHEMBL11962881 | 0.82 | GPR119 (0.55) | KMT2AALDH1A1MEN1GPR119USP2 | |
| Hydrochloric Acid SCHEMBL5237325 | 0.82 | USP2 (0.70) | MAPTALDH1A1USP2NPC1RAB9A | |
| SCHEMBL15368368 | 0.81 | MAPT (0.55) | MAPTKMT2AALDH1A1MEN1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060084176-A1 | Detection of uronium salts | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2006-04-20 | — | — | US | claimed |
| US-20230357249-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS WITH A TRICYCLIC CEREBLON LIGAND | UNIV MICHIGAN REGENTS (US) | 2023-11-09 | — | — | US | disclosed |
| US-9217938-B2 | Electrophotographic photosensitive member, process cartridge, electrophotographic apparatus and phthalocyanine crystal | CANON KABUSHIKI KAISHA (JP) | 2015-12-22 | — | — | US | disclosed |
| US-9217938-B2 | Electrophotographic photosensitive member, process cartridge, electrophotographic apparatus and phthalocyanine crystal | CANON KABUSHIKI KAISHA (JP) | 2015-12-22 | — | — | US | disclosed |
| US-20140170543-A1 | ELECTROPHOTOGRAPHIC PHOTOSENSITIVE MEMBER, PROCESS CARTRIDGE, ELECTROPHOTOGRAPHIC APPARATUS AND PHTHALOCYANINE CRYSTAL | CANON KABUSHIKI KAISHA (JP) | 2014-06-19 | — | — | US | disclosed |
| US-20140170543-A1 | ELECTROPHOTOGRAPHIC PHOTOSENSITIVE MEMBER, PROCESS CARTRIDGE, ELECTROPHOTOGRAPHIC APPARATUS AND PHTHALOCYANINE CRYSTAL | CANON KABUSHIKI KAISHA (JP) | 2014-06-19 | — | — | US | disclosed |
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-1985620-A1 | 10a-AZALIDE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2008-10-29 | — | — | EP | disclosed |
| US-20060084176-A1 | Detection of uronium salts | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2006-04-20 | — | — | US | disclosed |
| US-3993763-A | ALPHA-(CYCLIC TERTIARY AMINO-PHENYL)-ALIPHATIC ACIDS | CIBA-GEIGY CORPORATION (US) | 1976-11-23 | — | — | US | disclosed |
| US-3936467-A | ANTIINFLAMMATORY | CIBA-GEIGY CORPORATION (US) | 1976-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357249-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS WITH A TRICYCLIC CEREBLON LIGAND | AR, GPER1, CRBN | MAPT 3146/4885KMT2A 3389/4885ALDH1A1 291/4885 |
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | MAPT 4302/4885KMT2A 939/4885ALDH1A1 1939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.